Pharma channel feed – Endpoints News

Pharma channel feed

The Department of Defense could undermine FDA, giving the green light for experimental products

8 years ago

Senator Harris comes out swinging against Alkermes and its CEO, attacking an opioid drug franchise

8 years ago

Amgen is shaking up R&D (again), chopping 200 as Genentech targets 130 layoffs

8 years ago

Valeant hands off its controversial, $1B female libido drug to Sprout backers in sweetheart deal

8 years ago

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed therapy

8 years ago

Is Neurocrine primed for takeover? Revenue soars on Ingrezza sales

8 years ago

Valeant finally wins long-delayed FDA OK for its glaucoma drug, which is more good news for Aerie

8 years ago

GOP tax reform bill would repeal orphan drug research credits

8 years ago

FDA panel votes yes on Indivior’s opioid addiction drug

8 years ago

AstraZeneca inks a cardio drug development pact with mRNA specialist Moderna

8 years ago

Greek health minister takes issue with Roche's withdrawal of cancer medicine due to mandatory, retroactive discount

8 years ago

AstraZeneca gets an early green light on BTK blockbuster hopeful Calquence

8 years ago

Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact

8 years ago

Can tiny Mustang Bio compete on the CAR-T front with giants like Novartis and Gilead? Manny Litchman aims to find out

8 years ago

In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal

8 years ago

Mereo bags rights to the latest AstraZeneca castoff, shifts focus; Neos rejects buyout offer

8 years ago

Merck’s bad day: $310M for NotPetya, franchise drugs take a hit and now the EMA pushes back on Keytruda

8 years ago

With ‘breakthrough’ status and a handy nickname, BioMarin plots speedy PhIII for gene therapy

8 years ago

Brushing back biosims, a confident AbbVie outlines a blockbuster winning streak ahead for Humira

8 years ago

First Celgene, now Gilead can’t accurately forecast drug sales revenue. How bad is this?

8 years ago

In a pre-Halloween fright show, Celgene just scared the hell out of Wall Street — shares crater

8 years ago

Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

8 years ago

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

8 years ago

The Medicines Company brings out the ax, looking to jettison hundreds of jobs in top-to-bottom restructuring

8 years ago

First page Previous page 310 311 312313314 315 316 Next page Last page